The Archive · 32,142 records

Source documents — page 84 of 129

Source documents, page 84 of 129: records 20,751–21,000 of 32,142, titles O.

Browse by source, program, docket, document type or year.

Records 20,751–21,000 of 32,142

O

Objections to Scheduling Order — United States v. Shaquandra Woods, No. CR422-016-1 (Dkt. 284, S.D. Ga.)Objections to Scheduling Order — United States v. Shaquandra Woods, No. CR422-016-1 (Dkt.…
Objective 6 2026Archived source document: Objective 6 2026.
Obligating SLFRF Funds Through an Interagency Agreement — Treasury Quick Reference GuideTreasury quick reference on obligating SLFRF funds through an interagency agreement in…
Observations: Fiscal Year 2020 COVID-19 ContractingPage on first-time federal contractors and limited competition in fiscal year 2020…
Observations: Fiscal Year 2020 COVID-19 Federal ContractingObservations: Fiscal Year 2020 COVID-19 Federal Contracting: audit dated August 4, 2021. Full text…
Ocala Man Charged with Seaman's Manslaughter and Paycheck Protection Program FraudS.D. Fla. release, August 30, 2024: indictment charging Dustin Sean McCabe with seaman's…
Ocala Man Indicted For Fraud Relating To COVID-19 Relief FundsM.D. Fla. press release, December 9, 2022: Henry Troy Wade indicted on six wire fraud…
Ocala Man Indicted For Wire Fraud And Price Gouging Related To The Sale Of COVID-19 FacemasksM.D. Fla. press release, June 12, 2025: Frank Adriel Romero Leandro indicted for wire…
Ocala Woman Arrested For COVID FraudM.D. Fla. release, August 27, 2024: arrest of Lisa Yvette Starkes of Ocala on an…
Ocala Woman Indicted For Fraud Relating To COVID-19 Relief FundsRoger B. Handberg announced an indictment of Passion Lajodia Jackson of Ocala for wire…
Ocala Woman Pleads Guilty to Fraud Relating to COVID-19 Relief FundsDOJ release, September 12, 2023: Passion Lajodia Jackson of Ocala pleads guilty to wire…
Ocala Woman Sentenced to Two Years in Federal Prison for Theft of COVID Relief FundsDOJ release, December 14, 2023: Ocala woman Passion Lajodia Jackson sentenced to two…
OCC Procedures for Implementation of Section 515 Information Quality Act (Public Law 106-554)OCC procedures implementing Section 515 of the Information Quality Act (Public Law…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 32, Updated November 10, 2021)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 34, Updated November 17, 2021)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 35, Updated December 10, 2021)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 37, Updated December 21, 2021)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 38, Updated January 5, 2022)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 39, Updated January 14, 2022)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary Standards (ETS) on Health Care Employment and Vaccinations and Testing for Large Employers (R46288, Version 40, Updated January 26, 2022)Occupational Safety and Health Administration (OSHA): COVID-19 Emergency Temporary…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 10, Updated June 10, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 11, Updated June 11, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 12, Updated July 27, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 13, Updated October 20, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 15, Updated December 3, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 16, Updated January 14, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 18, Updated January 28, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 2)Archived source document: Occupational Safety and Health Administration (OSHA): Emergency…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 26, Updated April 27, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 28, Updated June 2, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 3, Updated April 8, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 30, Updated July 13, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 31, Updated September 13, 2021)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 5, Updated April 27, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 6, Updated May 7, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 7, Updated May 19, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS) and COVID-19 (R46288, Version 8, Updated May 28, 2020)Occupational Safety and Health Administration (OSHA): Emergency Temporary Standards (ETS)…
Ocean County Man Admits $21.7 Million Health Care Fraud Scheme and COVID-19 Wire Fraud SchemeD.N.J. press release, June 30, 2023: Alexander Schleider admits a $21.7 million DME…
Ocrolus Announces PPP Loan Forgiveness Solution With Built-in Audit Trail (June 2, 2020)Archived source: Ocrolus Announces PPP Loan Forgiveness Solution With Built-in Audit…
Ocrolus Inspect: new condition creation interface and Encompass integration (July 2, 2025)Archived source: Ocrolus Inspect: new condition creation interface and Encompass…
Ocrolus Raises $80 Million at $500 Million Valuation — Finovate (September 24, 2021)Ocrolus raised $80 million in Series C funding led by Fin VC, with $127 million in…
Ocrolus Raises $80M In Series C Funding To Scale Its Financial Services Focused Document Automation SolutionOcrolus announces $80 million in Series C funding led by Fin VC at a valuation north of…
Ocrolus — AI Workflow and Analytics Platform for LendersOcrolus home page: AI underwriting and document-analysis platform for lenders, with…
Oct 2019 - Panthera Monthly Operating ReportOct 2019 - Panthera Monthly Operating Report: document dated November 20, 2019. Full text and…
OCUGEN, INC. Form 10-K (Dec. 31, 2019)Ocugen, Inc. Form 10-K for fiscal 2019: reverse merger with Histogenics, eye-therapy…
OCUGEN, INC. Form 10-K (Dec. 31, 2020)Ocugen, Inc. Form 10-K for the fiscal year ended December 31, 2020 (File No. 001-36751):…
OCUGEN, INC. Form 10-K (Dec. 31, 2021)Ocugen, Inc. Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-36751):…
OCUGEN, INC. Form 10-Q (June 30, 2020)Ocugen, Inc. Form 10-Q for the quarter ended June 30, 2020 (File No. 001-36751):…
OCUGEN, INC. Form 10-Q (June 30, 2021)Ocugen, Inc. Form 10-Q for the quarter ended June 30, 2021 (File No. 001-36751):…
OCUGEN, INC. Form 10-Q (June 30, 2022)Ocugen, Inc. Form 10-Q for the quarter ended June 30, 2022 (File No. 001-36751): cash of…
OCUGEN, INC. Form 10-Q (March 31, 2020)Ocugen, Inc. Form 10-Q for the quarter ended March 31, 2020 (File No. 001-36751): net…
OCUGEN, INC. Form 10-Q (March 31, 2021)Ocugen, Inc. Form 10-Q for the quarter ended March 31, 2021 (File No. 001-36751): net…
OCUGEN, INC. Form 10-Q (March 31, 2022)Ocugen, Inc. Form 10-Q for the quarter ended March 31, 2022 (File No. 001-36751): cash of…
OCUGEN, INC. Form 10-Q (Sept. 30, 2020)Ocugen, Inc. Form 10-Q for the quarter ended September 30, 2020 (File No. 001-36751):…
OCUGEN, INC. Form 10-Q (Sept. 30, 2021)Ocugen, Inc. Form 10-Q for the quarter ended September 30, 2021 (File No. 001-36751):…
OCUGEN, INC. Form 10-Q (Sept. 30, 2022)Ocugen, Inc. Form 10-Q for the quarter ended September 30, 2022 (File No. 001-36751):…
Ocugen, Inc. Form 4 (April 18, 2022)Ocugen, Inc. Form 4 for director Ramesh Kumar, April 18, 2022: 7,500 options exercised…
Ocugen, Inc. Form 4 (April 19, 2021) — Kumar RameshOcugen, Inc. Form 4: director Ramesh Kumar acquired 7,500 shares at $0.51 and sold 7,500…
Ocugen, Inc. Form 4 (April 26, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella sold 350,000 shares on 04/26/2021 at a…
Ocugen, Inc. Form 4 (April 29, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Chief Financial Officer Sanjay Subramanian acquired 7,990 shares at…
Ocugen, Inc. Form 4 (April 29, 2021) — Tammara VijayOcugen, Inc. Form 4: Vijay Tammara exercised options and sold the shares on 04/29/2021…
Ocugen, Inc. Form 4 (April 30, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella sold shares on 04/30/2021 and 05/03/2021,…
Ocugen, Inc. Form 4 (Aug. 11, 2022)Ocugen, Inc. Form 4 for director Kirsten Castillo, August 11, 2022: 42,000 options…
Ocugen, Inc. Form 4 (Aug. 14, 2020) — Tammara VijayOcugen, Inc. Form 4: Senior Vice President Vijay Tammara granted options for 50,000…
Ocugen, Inc. Form 4 (Aug. 16, 2021) — Subramanian SanjayOcugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, August 16, 2021: 30,000…
Ocugen, Inc. Form 4 (Dec. 16, 2021) — Castillo KirstenOcugen, Inc. Form 4 for director Kirsten Castillo, December 16, 2021: option for 16,335…
Ocugen, Inc. Form 4 (Dec. 16, 2021) — Fernandes PrabhavathiOcugen, Inc. Form 4 for director Prabhavathi Fernandes, December 16, 2021: option to buy…
Ocugen, Inc. Form 4 (Dec. 16, 2021) — Kompella UdayOcugen, Inc. Form 4 for director Uday Kompella, December 16, 2021: option grant covering…
Ocugen, Inc. Form 4 (Dec. 16, 2021) — Zhang JungeOcugen, Inc. Form 4 for director Junge Zhang, December 16, 2021: option grant covering…
Ocugen, Inc. Form 4 (Dec. 16, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, December 16, 2022: 95,809 options exercised at…
Ocugen, Inc. Form 4 (Feb. 14, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, February 14, 2022: 90,000 options exercised at…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Castillo KirstenOcugen, Inc. (OCGN) Form 4: director Kirsten Castillo acquired an option for 126,000…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Fernandes PrabhavathiOcugen, Inc. Form 4: director Prabhavathi Fernandes reports a 126,000-share option at…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella acquired a 126,000-share option at $1.83 on…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Kumar RameshOcugen, Inc. (OCGN) Form 4: director Ramesh Kumar acquired an option to buy 126,000…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Musunuri ShankarOcugen, Inc. Form 4: Chief Executive Officer Shankar Musunuri reports an option for…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Potti ManishOcugen, Inc. Form 4: director Manish Potti's 126,000-share option at $1.83, acquired…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Chief Financial Officer Sanjay Subramanian granted an option for…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Tammara VijayOcugen, Inc. Form 4: Senior Vice President Vijay Tammara granted an option for 220,500…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Taspolatoglu SuhaOcugen, Inc. Form 4: director Suha Taspolatoglu's option for 126,000 shares at $1.83,…
Ocugen, Inc. Form 4 (Jan. 1, 2021) — Zhang JungeOcugen, Inc. Form 4: director Junge Zhang reports an option for 126,000 shares at $1.83…
Ocugen, Inc. Form 4 (Jan. 18, 2022)Ocugen, Inc. Form 4 for director Ramesh Kumar, January 18, 2022: 7,500 options exercised…
Ocugen, Inc. Form 4 (Jan. 29, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Chief Financial Officer Sanjay Subramanian acquired 35,591 shares at…
Ocugen, Inc. Form 4 (July 14, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, July 14, 2022: 150,000 options exercised at $0.33…
Ocugen, Inc. Form 4 (July 15, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Sanjay Subramanian acquired 31,086 shares at $0.34 and sold them at…
Ocugen, Inc. Form 4 (July 18, 2022)Ocugen, Inc. Form 4 for director Ramesh Kumar, July 18, 2022: 7,500 options exercised at…
Ocugen, Inc. Form 4 (July 19, 2021) — Kumar RameshOcugen, Inc. (OCGN) Form 4: director Ramesh Kumar acquired 7,500 shares at $0.51 and sold…
Ocugen, Inc. Form 4 (July 30, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella acquired 10,000 shares at $1.83 and sold…
Ocugen, Inc. Form 4 (June 15, 2021) — Potti ManishOcugen, Inc. Form 4: director Manish Potti exercised a warrant for 95,880 shares at $6.30…
Ocugen, Inc. Form 4 (June 15, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Sanjay Subramanian acquired 31,000 shares at $0.34 on 06/15/2021 and…
Ocugen, Inc. Form 4 (June 25, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella acquired 10,000 shares at $1.83 and sold…
Ocugen, Inc. Form 4 (June 7, 2021) — Castillo KirstenOcugen, Inc. Form 4: director Kirsten Castillo sold 10,000 shares at $10 on 06/07/2021…
Ocugen, Inc. Form 4 (June 7, 2021) — Musunuri ShankarOcugen, Inc. Form 4: Shankar Musunuri sold 7,758 shares on 06/07/2021 and 22,800 on…
Ocugen, Inc. Form 4 (March 16, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, March 16, 2022: 81,823 options exercised at $0.33…
Ocugen, Inc. Form 4 (March 18, 2022)Ocugen, Inc. Form 4 for Jessica Crespo, CAO/SVP, Finance, March 18, 2022: 22,940…
Ocugen, Inc. Form 4 (March 21, 2022)Ocugen, Inc. Form 4 for director Marna Whittington, March 21, 2022: option to buy 106,383…
Ocugen, Inc. Form 4 (March 3, 2022)Ocugen, Inc. Form 4 for director Junge Zhang, March 3, 2022: options for 39,000 and…
Ocugen, Inc. Form 4 (March 5, 2021) — Potti ManishOcugen, Inc. Form 4: director Manish Potti acquired 21,000 shares at $0.51 and 7,000 at…
Ocugen, Inc. Form 4 (May 13, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, May 13, 2022: 125,000 options exercised at $0.33…
Ocugen, Inc. Form 4 (May 14, 2021) — Subramanian SanjayOcugen, Inc. Form 4: Sanjay Subramanian acquired 31,000 shares at $0.34 and sold them at…
Ocugen, Inc. Form 4 (May 25, 2021) — Fernandes PrabhavathiOcugen, Inc. Form 4: director Prabhavathi Fernandes exercised options for 19,500 and…
Ocugen, Inc. Form 4 (May 28, 2021) — Kompella UdayOcugen, Inc. Form 4: director Uday Kompella acquired 7,191 shares at $1.88 and sold 7,191…
Ocugen, Inc. Form 4 (May 3, 2021) — Musunuri ShankarOcugen, Inc. Form 4: Shankar Musunuri acquired and sold 195,809 shares on 05/03/2021, the…
Ocugen, Inc. Form 4 (May 3, 2021) — Potti ManishOcugen, Inc. Form 4: director Manish Potti sold 28,000 shares owned directly and 60,000…
Ocugen, Inc. Form 4 (May 4, 2021) — Tammara VijayOcugen, Inc. Form 4: Vijay Tammara exercised options and sold the shares on 05/04/2021 at…
Ocugen, Inc. Form 4 (Nov. 1, 2021) — Kompella UdayOcugen, Inc. Form 4 for director Uday Kompella, November 1, 2021: two sales of 25,000…
Ocugen, Inc. Form 4 (Nov. 1, 2021) — Musunuri ShankarOcugen, Inc. Form 4, Chief Executive Officer Shankar Musunuri, November 1, 2021: 115,367…
Ocugen, Inc. Form 4 (Nov. 16, 2021) — Musunuri ShankarOcugen, Inc. Form 4, Shankar Musunuri, November 16, 2021: 115,000 shares sold and a…
Ocugen, Inc. Form 4 (Nov. 16, 2021) — Subramanian SanjayOcugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, November 16, 2021:…
Ocugen, Inc. Form 4 (Nov. 16, 2021) — Zhang JungeOcugen, Inc. Form 4 for director Junge Zhang, November 16, 2021: Gupiao Trust exercised…
Ocugen, Inc. Form 4 (Nov. 2, 2021) — Castillo KirstenOcugen, Inc. Form 4 for director Kirsten Castillo, November 2, 2021: 15,000 shares sold…
Ocugen, Inc. Form 4 (Nov. 2, 2021) — Potti ManishOcugen, Inc. Form 4 for director Manish Potti, November 2, 2021: 63,429 shares sold at a…
Ocugen, Inc. Form 4 (Nov. 2, 2021) — Zhang JungeOcugen, Inc. Form 4 for director Junge Zhang, November 2, 2021: 149,700 shares sold by…
Ocugen, Inc. Form 4 (Nov. 3, 2021) — Zhang JungeOcugen, Inc. Form 4 for director Junge Zhang, November 3, 2021: 150,300 shares sold by…
Ocugen, Inc. Form 4 (Oct. 14, 2022)Ocugen, Inc. Form 4, Shankar Musunuri, October 14, 2022: 100,000 options exercised at…
Ocugen, Inc. Form 4 (Oct. 15, 2021) — Musunuri ShankarOcugen, Inc. Form 4, Chief Executive Officer Shankar Musunuri, October 15, 2021: 125,000…
Ocugen, Inc. Form 4 (Oct. 15, 2021) — Subramanian SanjayOcugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, October 15, 2021: 7,990…
Ocugen, Inc. Form 4 (Oct. 18, 2021) — Kompella UdayOcugen, Inc. Form 4 for director Uday Kompella, October 18, 2021: 200,000 shares sold…
Ocugen, Inc. Form 4 (Oct. 18, 2021) — Kumar RameshOcugen, Inc. Form 4 for director Ramesh Kumar, October 18, 2021: 7,500 options exercised…
Ocugen, Inc. Form 4 (Oct. 21, 2021) — Kompella UdayOcugen, Inc. Form 4 for director Uday Kompella, October 21, 2021: 1,898 shares sold…
Ocugen, Inc. Form 4 (Oct. 25, 2021) — Kompella UdayOcugen, Inc. Form 4 for director Uday Kompella, October 25, 2021: 46,371 and 25,000…
Ocugen, Inc. Form 4 (Oct. 26, 2021) — Subramanian SanjayOcugen, Inc. Form 4, Chief Financial Officer Sanjay Subramanian, October 26, 2021: 10,000…
Ocugen, Inc. Form 4 (Oct. 6, 2022)Ocugen, Inc. Form 4 for director Ramesh Kumar, October 6, 2022: 4,500 options exercised…
Ocugen, Inc. Form 4 (Sept. 15, 2021) — Musunuri ShankarOcugen, Inc. Form 4, Chief Executive Officer Shankar Musunuri, September 15, 2021:…
OCUGEN, INC. Form 8-K (April 12, 2022)Ocugen, Inc. Form 8-K dated April 12, 2022: press release updating the Phase 2/3 study of…
OCUGEN, INC. Form 8-K (April 13, 2020)Ocugen, Inc. Form 8-K (April 13, 2020): Item 7.01 Regulation FD report furnishing a…
OCUGEN, INC. Form 8-K (April 14, 2021)Ocugen, Inc. Form 8-K dated April 14, 2021: stockholders approve raising authorized…
OCUGEN, INC. Form 8-K (April 15, 2022)Ocugen, Inc. Form 8-K: Second Amendment with Bharat Biotech expands the COVAXIN territory…
OCUGEN, INC. Form 8-K (April 19, 2021)Ocugen, Inc. Form 8-K dated April 19, 2021: 2021 Performance Options granted to officers,…
OCUGEN, INC. Form 8-K (April 20, 2022)Ocugen, Inc. Form 8-K dated April 20, 2022: presentation to be posted on the company…
OCUGEN, INC. Form 8-K (April 21, 2021)Ocugen, Inc. Form 8-K dated April 21, 2021: press release on Bharat Biotech’s second…
OCUGEN, INC. Form 8-K (April 22, 2020)Ocugen, Inc. Form 8-K (April 22, 2020): warrant exchange for 21,920,820 shares and…
OCUGEN, INC. Form 8-K (April 23, 2021)Ocugen, Inc. Form 8-K dated April 23, 2021: registered direct offering of 10,000,000…
OCUGEN, INC. Form 8-K (April 3, 2020)Ocugen, Inc. Form 8-K (April 3, 2020): director resignation, two new Class III directors…
OCUGEN, INC. Form 8-K (April 30, 2020)Ocugen, Inc. Form 8-K (April 30, 2020): $421,415.00 Paycheck Protection Program loan from…
OCUGEN, INC. Form 8-K (April 4, 2022)Ocugen, Inc. Form 8-K dated April 4, 2022: investor presentation attached as Exhibit 99.1…
OCUGEN, INC. Form 8-K (Aug. 10, 2020)Ocugen, Inc. Form 8-K dated August 10, 2020: Orphan Drug Designation for OCU400 in PDE6B…
OCUGEN, INC. Form 8-K (Aug. 14, 2020) — Item 1.01Ocugen, Inc. Form 8-K dated August 14, 2020: At Market Issuance Sales Agreement for up to…
OCUGEN, INC. Form 8-K (Aug. 14, 2020) — Item 2.02Ocugen, Inc. Form 8-K dated August 14, 2020: press release on financial results for the…
OCUGEN, INC. Form 8-K (Aug. 16, 2022)Ocugen, Inc. Form 8-K dated August 16, 2022: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Aug. 17, 2020)Ocugen, Inc. Form 8-K dated August 17, 2020: investor presentation furnished under…
OCUGEN, INC. Form 8-K (Aug. 17, 2022)Ocugen, Inc. Form 8-K dated August 17, 2022: presentation to be posted on the company…
OCUGEN, INC. Form 8-K (Aug. 25, 2020)Ocugen, Inc. Form 8-K dated August 25, 2020: patent issued for preservative free ocular…
OCUGEN, INC. Form 8-K (Aug. 26, 2022)Ocugen, Inc. Form 8-K dated August 26, 2022: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Aug. 4, 2020)Ocugen, Inc. Form 8-K dated August 4, 2020: preliminary cash and debt estimates as of…
OCUGEN, INC. Form 8-K (Aug. 5, 2022)Ocugen, Inc. Form 8-K dated August 5, 2022: financial results for the quarter ended June…
OCUGEN, INC. Form 8-K (Aug. 6, 2021)Ocugen, Inc. Form 8-K dated August 6, 2021: results for the quarter ended June 30, 2021,…
OCUGEN, INC. Form 8-K (Dec. 15, 2021)Ocugen, Inc. Form 8-K dated December 15, 2021: presentation posted on the company…
OCUGEN, INC. Form 8-K (Dec. 15, 2022)Ocugen, Inc. Form 8-K: orphan drug designations for OCU400 and agreement on the NeoCart…
OCUGEN, INC. Form 8-K (Dec. 22, 2020)Ocugen, Inc. Form 8-K dated December 22, 2020: binding letter of intent with Bharat…
OCUGEN, INC. Form 8-K (Dec. 23, 2020)Ocugen, Inc. Form 8-K dated December 23, 2020: annual meeting voting results;…
OCUGEN, INC. Form 8-K (Dec. 30, 2021)Ocugen, Inc. Form 8-K dated December 30, 2021: Bharat Biotech posts Phase 2/3 COVAXIN…
OCUGEN, INC. Form 8-K (Dec. 9, 2021) — Item 5.02Ocugen, Inc. Form 8-K (Item 5.02): director Suha Taspolatoglu resigns from the Board and…
OCUGEN, INC. Form 8-K (Dec. 9, 2021) — Item 8.01Ocugen, Inc. Form 8-K dated December 9, 2021: acceptance of an Investigational New Drug…
OCUGEN, INC. Form 8-K (Feb. 14, 2020)Ocugen, Inc. Form 8-K (February 14, 2020): Item 7.01 Regulation FD disclosure furnishing…
OCUGEN, INC. Form 8-K (Feb. 14, 2022)Ocugen, Inc. Form 8-K dated February 14, 2022: presentation to be posted on the company…
OCUGEN, INC. Form 8-K (Feb. 18, 2022)Ocugen, Inc. Form 8-K: U.S. Food and Drug Administration lifts the clinical hold on the…
OCUGEN, INC. Form 8-K (Feb. 2, 2021)Ocugen, Inc. Form 8-K dated February 2, 2021: Co-Development, Supply and…
OCUGEN, INC. Form 8-K (Feb. 2, 2022)Ocugen, Inc. Form 8-K dated February 2, 2022: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Feb. 22, 2022) — Item 1.01Ocugen, Inc. Form 8-K: underwriting agreement with Cantor Fitzgerald & Co. for 15,973,420…
OCUGEN, INC. Form 8-K (Feb. 22, 2022) — Item 8.01Ocugen, Inc. Form 8-K dated February 22, 2022: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Feb. 23, 2021)Ocugen, Inc. Form 8-K dated February 23, 2021: European Commission orphan medicinal…
OCUGEN, INC. Form 8-K (Feb. 25, 2022)Ocugen, Inc. Form 8-K dated February 25, 2022: fourth quarter and fiscal 2021 results…
OCUGEN, INC. Form 8-K (Feb. 5, 2021)Ocugen, Inc. Form 8-K dated February 5, 2021: investor presentation furnished under…
OCUGEN, INC. Form 8-K (Feb. 7, 2021)Ocugen, Inc. Form 8-K dated February 7, 2021: registered direct offering of 3,000,000…
OCUGEN, INC. Form 8-K (Jan. 1, 2020)Ocugen, Inc. Form 8-K (event date January 1, 2020): non-employee director pay, restated…
OCUGEN, INC. Form 8-K (Jan. 12, 2021)Ocugen, Inc. Form 8-K dated January 12, 2021: Board withdraws Item 2, the authorized…
OCUGEN, INC. Form 8-K (Jan. 12, 2022)Ocugen, Inc. Form 8-K dated January 12, 2022: Emory University study of COVAXIN booster…
OCUGEN, INC. Form 8-K (Jan. 24, 2022)Ocugen, Inc. Form 8-K: non-binding letter of intent with Liminal Biosciences for a…
OCUGEN, INC. Form 8-K (Jan. 5, 2021)Ocugen, Inc. Form 8-K dated January 5, 2021: investor presentation furnished under…
OCUGEN, INC. Form 8-K (Jan. 6, 2022)Ocugen, Inc. Form 8-K dated January 6, 2022: investor presentation posted on the company…
OCUGEN, INC. Form 8-K (Jan. 8, 2021)Ocugen, Inc. Form 8-K dated January 8, 2021: Nasdaq confirms regained compliance with the…
OCUGEN, INC. Form 8-K (Jan. 8, 2022)Ocugen, Inc. Form 8-K: Bharat Biotech posts Phase 2 booster-dose results for COVAXIN in…
OCUGEN, INC. Form 8-K (July 15, 2021)Ocugen, Inc. Form 8-K dated July 15, 2021: rolling submission to Health Canada for…
OCUGEN, INC. Form 8-K (July 16, 2020)Ocugen, Inc. Form 8-K (July 16, 2020): corporate presentation with preliminary estimates…
OCUGEN, INC. Form 8-K (July 2, 2021) — Item 5.07Ocugen, Inc. Form 8-K dated July 2, 2021: 2021 annual meeting voting results after…
OCUGEN, INC. Form 8-K (July 2, 2021) — Item 8.01Ocugen, Inc. Form 8-K dated July 2, 2021: press release on Bharat Biotech’s Phase 3 study…
OCUGEN, INC. Form 8-K (July 20, 2021)Ocugen, Inc. Form 8-K dated July 20, 2021: investor presentation attached as Exhibit 99.1…
OCUGEN, INC. Form 8-K (July 27, 2020)Ocugen, Inc. Form 8-K dated July 27, 2020: Orphan Drug Designation for OCU400 in…
OCUGEN, INC. Form 8-K (July 9, 2021)Ocugen, Inc. Form 8-K dated July 9, 2021: investor presentation attached as Exhibit 99.1…
OCUGEN, INC. Form 8-K (June 1, 2020)Ocugen, Inc. Form 8-K (June 1, 2020): Item 8.01 press release on the decision to…
OCUGEN, INC. Form 8-K (June 1, 2021)Ocugen, Inc. Form 8-K dated June 1, 2021: First Amendment with Bharat Biotech expands…
OCUGEN, INC. Form 8-K (June 10, 2021)Ocugen, Inc. Form 8-K dated June 10, 2021: plan to pursue a biologics license application…
OCUGEN, INC. Form 8-K (June 10, 2022)Ocugen, Inc. Form 8-K: At Market Issuance Sales Agreement for common stock with an…
OCUGEN, INC. Form 8-K (June 12, 2020)Ocugen, Inc. Form 8-K (June 12, 2020): Cantor Fitzgerald & Co. Controlled Equity Offering…
OCUGEN, INC. Form 8-K (June 15, 2020)Ocugen, Inc. Form 8-K (June 15, 2020): workforce reduction of five employees, one-third…
OCUGEN, INC. Form 8-K (June 3, 2020)Ocugen, Inc. Form 8-K (June 3, 2020): Item 7.01 Regulation FD report furnishing an…
OCUGEN, INC. Form 8-K (June 7, 2022)Ocugen, Inc. Form 8-K dated June 7, 2022: annual meeting results electing two Class II…
OCUGEN, INC. Form 8-K (March 1, 2021)Ocugen, Inc. Form 8-K dated March 1, 2021: Series B Convertible Preferred Stock sold to…
OCUGEN, INC. Form 8-K (March 11, 2022)Ocugen, Inc. Form 8-K dated March 11, 2022: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (March 16, 2021)Ocugen, Inc. Form 8-K dated March 16, 2021: Special Meeting adjourned to April 14, 2021…
OCUGEN, INC. Form 8-K (March 17, 2022)Ocugen, Inc. Form 8-K: Manish Potti not standing for re-election, Marna Whittington joins…
OCUGEN, INC. Form 8-K (March 18, 2021)Ocugen, Inc. Form 8-K dated March 18, 2021: results for the year ended December 31, 2020…
OCUGEN, INC. Form 8-K (March 2, 2022)Ocugen, Inc. Form 8-K: Chief Financial Officer Sanjay Subramanian resigns; Jessica Crespo…
OCUGEN, INC. Form 8-K (March 27, 2020)Ocugen, Inc. Form 8-K (March 27, 2020): Item 2.02 press release on results for the year…
OCUGEN, INC. Form 8-K (March 3, 2021)Ocugen, Inc. Form 8-K dated March 3, 2021: press release on Bharat Biotech’s first…
OCUGEN, INC. Form 8-K (March 31, 2021)Ocugen, Inc. Form 8-K dated March 31, 2021: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (May 19, 2021)Ocugen, Inc. Form 8-K dated May 19, 2021: investor presentation attached as Exhibit 99.1…
OCUGEN, INC. Form 8-K (May 23, 2022)Ocugen, Inc. Form 8-K dated May 23, 2022: U.S. Food and Drug Administration lifts the…
OCUGEN, INC. Form 8-K (May 24, 2022)Ocugen, Inc. Form 8-K dated May 24, 2022: press release introducing the NeoCart cell…
OCUGEN, INC. Form 8-K (May 6, 2022)Ocugen, Inc. Form 8-K dated May 6, 2022: financial results for the quarter ended March…
OCUGEN, INC. Form 8-K (May 7, 2021) — Item 2.02Ocugen, Inc. Form 8-K dated May 7, 2021: press release on financial results for the…
OCUGEN, INC. Form 8-K (May 7, 2021) — Item 8.01Ocugen, Inc. Form 8-K dated May 7, 2021: investor presentation attached as Exhibit 99.1…
OCUGEN, INC. Form 8-K (May 8, 2020) — Item 1.01Ocugen, Inc. Form 8-K (May 8, 2020): Controlled Equity Offering Sales Agreement with…
OCUGEN, INC. Form 8-K (May 8, 2020) — Item 2.02Ocugen, Inc. Form 8-K (May 8, 2020): Item 2.02 press release on results for the quarter…
OCUGEN, INC. Form 8-K (Nov. 1, 2022)Ocugen, Inc. Form 8-K dated November 1, 2022: presentations and posters furnished for the…
OCUGEN, INC. Form 8-K (Nov. 15, 2021)Ocugen, Inc. Form 8-K dated November 15, 2021: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Nov. 2, 2021)Ocugen, Inc. Form 8-K dated November 2, 2021: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Nov. 26, 2021)Ocugen, Inc. Form 8-K dated November 26, 2021: press release updating the FDA application…
OCUGEN, INC. Form 8-K (Nov. 5, 2021)Ocugen, Inc. Form 8-K dated November 5, 2021: Emergency Use Authorization request for…
OCUGEN, INC. Form 8-K (Nov. 6, 2020) — Item 2.02Ocugen, Inc. Form 8-K dated November 6, 2020: press release on financial results for the…
OCUGEN, INC. Form 8-K (Nov. 6, 2020) — Item 7.01Ocugen, Inc. Form 8-K dated November 6, 2020: investor presentation furnished under…
OCUGEN, INC. Form 8-K (Nov. 8, 2021)Ocugen, Inc. Form 8-K dated November 8, 2021: Investigational New Drug application for a…
OCUGEN, INC. Form 8-K (Nov. 8, 2022) — Item 2.02Ocugen, Inc. Form 8-K (Item 2.02) dated November 8, 2022: financial results for the…
OCUGEN, INC. Form 8-K (Nov. 8, 2022) — Item 8.01Ocugen, Inc. Form 8-K (Item 8.01) dated November 8, 2022: presentation attached as…
OCUGEN, INC. Form 8-K (Nov. 9, 2021) — Item 2.02Ocugen, Inc. Form 8-K dated November 9, 2021: results for the quarter ended September 30,…
OCUGEN, INC. Form 8-K (Nov. 9, 2021) — Item 8.01Ocugen, Inc. Form 8-K dated November 9, 2021: investor presentation attached as Exhibit…
OCUGEN, INC. Form 8-K (Oct. 20, 2020)Ocugen, Inc. Form 8-K dated October 20, 2020: preliminary cash and debt estimates as of…
OCUGEN, INC. Form 8-K (Oct. 27, 2021)Ocugen, Inc. Form 8-K dated October 27, 2021: Investigational New Drug application for a…
OCUGEN, INC. Form 8-K (Oct. 6, 2020)Ocugen, Inc. Form 8-K dated October 6, 2020: agreement with Kemwell Biopharma Pvt. Ltd.…
OCUGEN, INC. Form 8-K (Sept. 14, 2022)Ocugen, Inc. Form 8-K dated September 14, 2022: press release on publication of a…
OCUGEN, INC. Form 8-K (Sept. 15, 2021)Ocugen, Inc. Form 8-K dated September 15, 2021: update on the Health Canada submission…
OCUGEN, INC. Form 8-K (Sept. 23, 2022)Ocugen, Inc. Form 8-K: exclusive license agreement with The Washington University for…
OCUGEN, INC. Form 8-K (Sept. 29, 2021)Ocugen, Inc. Form 8-K dated September 29, 2021: COVAXIN supply agreement with Bharat…
OCUGEN, INC. Form 8-K (Sept. 8, 2020)Ocugen, Inc. Form 8-K dated September 8, 2020: Nasdaq grants until March 8, 2021 to…
OCUGEN, INC. Form 8-K (Sept. 8, 2021)Ocugen, Inc. Form 8-K dated September 8, 2021: investor presentation attached as Exhibit…
Ocugen, Inc., Form 10-K, fiscal year ended December 31, 2025Archived source document: Ocugen, Inc., Form 10-K, fiscal year ended December 31, 2025.
ODA Shuttered Venue Operators Grant SystemSBA Privacy Impact Assessment, March 10, 2021 (modified April 19, 2021), for the…
ODR&R - Disaster Recovery - Economic Injury Disaster Loan (EIDL)SBA Economic Injury Disaster Loan information sheet: up to $2 million in working capital,…
OECD, "Inclusive Growth Review of Korea: Creating Opportunities for All"OECD (2021) Inclusive Growth Review of Korea: Creating Opportunities for All, published…
Oei 06 22 00040 the Provider Relief Fund Helped Select Nursing Homes Maintain Services During ThOei 06 22 00040 the Provider Relief Fund Helped Select Nursing Homes Maintain Services…: OIG…
OEIG Investigation No. 22-02050: Investigative Summary Report (Candice Brumfield)OEIG Investigation No. 22-02050: Investigative Summary Report (Candice Brumfield).
OEIG Investigation No. 22-02157: Investigative Summary Report (Arnita Rudd)OEIG Investigation No. 22-02157: Investigative Summary Report (Arnita Rudd).
OEM and private label orders are welcomeOEM and private label orders are welcome: website printout (4 pages) dated May 20, 2021. Full text…
Of An Order (I) Authorizing The Retention AndOf An Order (I) Authorizing The Retention And: source document dated July 31, 2024, lender…
of Appeals for the Fifth Circuit from this Court’s December 6 , 2022 , Memorandumof Appeals for the Fifth Circuit from this Court’s December 6 , 2022 , Memorandum: source…
of Appellate Procedure. We cannot accept motions submitted underFifth Circuit clerk's letter of January 21, 2022 on the appeal in U.S. Navy SEALs 1-26 v.…
of its subsidiaries (collectively, the “Debtors”) filed the Motion of the Debtors for Entry of anof its subsidiaries (collectively, the “Debtors”) filed the Motion of the Debtors for Entry of an…
of Ohio do not indicate that the Board of Professional Conduct has filed a reportof Ohio do not indicate that the Board of Professional Conduct has filed a report: court filing.…
of the Mail Date if any informat ion is incorrect. Reporting incorrect informa tion may result in aof the Mail Date if any informat ion is incorrect. Reporting incorrect informa tion may result……
Of Withdrawal Of Motion For Relief From The AutomaticWVEDA notice withdrawing its motion for stay relief to foreclose, In re Panthera…
Office Hours — American Rescue Plan Grant Liquidation ExtensionsDepartment of Education office hours transcript on requesting American Rescue Plan…
Office of Attorney General 2019 - 2021 Biennial Report (North Dakota)Office of Attorney General 2019 - 2021 Biennial Report (North Dakota).
Office of Auditor of StateOffice of Auditor of State: report dated October 4, 2023, 58 pages. Full text and citation…
Office of Chief Counsel, Internal Revenue Service Memorandum — Number AM 2023-007IRS Office of Chief Counsel memorandum AM 2023-007 on whether OSHA COVID-19…
Office of Economic Development & CompetitivenessWashington State Department of Commerce OEDC slides, 12/2024: small business programs and…
Office of Elementary and Secondary Education — New Hampshire Department of Education Waiver RequestNew Hampshire Department of Education's 3/13/2024 waiver request on education maintenance…
Office of Firearm Safety and Violence Prevention 2023 reportWashington Office of Firearm Safety and Violence Prevention 2023 report to the…
Office of Inspector General 2020 Audit Division Oversight PlanSBA OIG 2020 Audit Division Oversight Plan: audits in progress and planned, including…
Office of Inspector General Audits Division Oversight Plan for 2019SBA OIG 2019 Audits Division Oversight Plan: audits in progress and planned, including…